Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Price Target at $54.63

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been assigned an average rating of “Buy” from the ten analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $58.5556.

A number of research analysts have issued reports on the stock. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Monday, March 9th. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Wedbush lifted their price target on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research report on Monday. Finally, Truist Financial set a $68.00 price target on Maze Therapeutics in a research note on Tuesday.

Maze Therapeutics Stock Down 1.7%

Shares of Maze Therapeutics stock opened at $50.39 on Friday. The company has a 50 day moving average price of $45.31 and a 200 day moving average price of $36.41. The firm has a market capitalization of $2.42 billion, a P/E ratio of -2.41 and a beta of 4.47. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $53.65.

Insider Transactions at Maze Therapeutics

In related news, CMO Harold Bernstein sold 45,000 shares of the stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Atul Dandekar sold 72,400 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the transaction, the insider owned 10,503 shares in the company, valued at approximately $426,001.68. This trade represents a 87.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 230,000 shares of company stock worth $9,768,292 over the last three months.

Institutional Trading of Maze Therapeutics

Large investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Maze Therapeutics in the fourth quarter worth $145,000. Invesco Ltd. lifted its position in Maze Therapeutics by 1.5% during the fourth quarter. Invesco Ltd. now owns 134,033 shares of the company’s stock valued at $5,553,000 after purchasing an additional 1,971 shares during the period. ADAR1 Capital Management LLC lifted its position in Maze Therapeutics by 589.3% during the fourth quarter. ADAR1 Capital Management LLC now owns 179,532 shares of the company’s stock valued at $7,438,000 after purchasing an additional 153,487 shares during the period. XTX Topco Ltd boosted its holdings in Maze Therapeutics by 22.9% in the fourth quarter. XTX Topco Ltd now owns 33,021 shares of the company’s stock valued at $1,368,000 after purchasing an additional 6,154 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in Maze Therapeutics in the fourth quarter valued at $2,536,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.